Comprehensive Case Management Reassessment
|
|
|
- Ira Townsend
- 10 years ago
- Views:
Transcription
1 Comprehensive Case Management Reassessment Reassessment Date: Date of previous Assessment/Reassessment: Name: Client ID # Address: If Reassessment early or late explain: Current HIV Status: Asymptomatic Symptomatic AIDS At Risk CD4 Count: Date: Viral Load: Date: Method of Verification: Describe client s current situation: Emergency Contact: Phone # Relationship: Aware of Status? Y N Is there a Release of Information? Y N Date of Release: Address: 1
2 List all Service Providers that were involved in the last 180 days: Agency Type of Service Contact Phone # Case Conference Date Release of Information Expiration Date Identify Client s Collaterals/Children: *If any new children (under the age of 21) have moved into the household in the last 180 days, complete Child Assessment. Children s to Aware of Date Children s In Household Assessment Name Relationship Household Status Assessment Y/N Completed Y/N Y/N Completed Y/N 2
3 NEEDS REASSESSMENT For each area, review client s current status, and comment on any changes in client s functioning, needs and resources. Where appropriate, include information about the family support system. Comment on all areas checked and identify progress on goal areas for the previous quarter. Provide a brief summary for each section. * = not previously addressed; client not ready; in process; or, other with detailed information. HEALTH CARE * ed Primary Health Care Provider Identify: Date of last primary care appointment: Is client keeping appointments with primary care provider? Y N Inconsistent : Means of Verification: Current Hospital Preference: Complementary/Alternative Therapies Clinical Trials TB Testing/Treatment OB/GYN Identify Provider: Date of Last Exam: Date of last PAP: Test Results: Is Client Pregnant? Yes No Due Date: If yes, is client receiving prenatal care? Yes No If yes, has AZT Therapy been discussed? Yes No Family Planning STD Testing/Treatment 3
4 HEALTH CARE * ed Hepatitis Testing/Treatment Home Care Hospice Nutrition Dental Vision Other: (Fill in spaces below) Medications Identify current medication See next page specifically for medication Does client have access to medication? Y N Inconsistent If No or Inconsistent, : Does client need education in this area? Y N : 4
5 MEDICATIONS: Is client adhering to HIV medication regimen? Y N Inconsistent Unclear : Is assistance needed? Y N Identify: Antiretroviral medications Protease Inhibitors (PI) Date Started Dosage/Frequency Agenerase (amprenavir, APV) Aptivus (tipranavir, TPV) Crixivan (idinavir, IDV) Fortovase (saquinavir, SQV-soft gel cap) Invirase (saquinavir, SQV- hard gel cap) Kaletra (lopinavir/ritonavir, LPV/r) Lexiva (fosamprenavir, FPV) Norvir (ritonavir, RTV) Reyataz (atazanavir, ATV) Viracept (nelfinavir, NFV) Non Nucleoside Reverse Transcriptase Inhibitors (nnrti) Date Started Dosage/Frequency Rescriptor (delavirdine, DLV) Sustiva (efavirenz, EFV) Viramune (nevirapine, NVP) Nucleoside/nucleotide Reverse Transcriptase Inhibitors (NRTI) Date Started Dosage/Frequency Combivir (zidovudine + lamivudine, AZT + 3TC) Emtriva (emtricitabine, FTC) Epivir (lamivudine, 3TC) Epzicom (abacavir + lamivudine, ABC + 3TC) Hivid (zalcitabine, ddc) Retrovir (zidovudine, AZT or ZDV) Trizivir (abacavir + zidovudine + lamivudine, ABC + AZT + 3TC) Truvada (tenofovir + emtricitabine, TDF + FTC) VIDEX (didanosine, ddi) VIDEX EC (didanosine:delayed-release capsules, ddi) Viread (tenofovir DF, TDF) Zerit (stavudine, d4t) Zerit XR (stavudine:delayed-release, d4t) Ziagen (abacavir, ABC) Entry / Fusion Inhibitors Date Started Dosage/Frequency Fuzeon (enfuvirtide, ENF) The AIDS Institute updates the Medication List form on a quarterly basis for use with assessments and reassessments. This page should be replaced with an the most recent copy of the updated medication list. 5
6 OTHER MEDICATIONS (All other medications including TB, Psychotropic, etc.) Is client adhering to HIV medication regimen? Y N Inconsistent Unclear : Is assistance needed? Y N Identify: Name Date Started Dosage/Frequency 6
7 HEALTH CARE continued Collateral (especially children) Status/s: Current Overall Status/Barriers: 7
8 FINANCIAL/ ENTITLEMENTS * ed (Include $ Amounts) Food Stamps Medicaid ADAP SSI/SSD/VA Benefits Unemployment Benefits Home Relief/Safety Net TANF DAS (LDSS) Rent Enhancement Financial Management Other: (Fill in Section Below) If on MA spend down, Identify amount: Indicate methods of spend down: Current Overall Status/s: 8
9 INDEPENDENT LIVING Date of most recent home: visit: * ed Current housing status: Permanent Transitional Homeless Describe: Appropriate/Affordable Eviction ice Owes Back Rent Housing Repairs ed Advocacy with Landlord Out of Pocket Rent Expense Utilities Phone Transportation Other: Current Overall Status/Barriers: 9
10 SUBSTANCE USE * ed Is client currently using substances? Yes No (What/How Much/How Often): Out Patient Treatment Residential Treatment MMTP (Dosage ) AA/NA Meetings DETOX le Exchange Other: (Fill in section below) If yes to any of the above, indicate frequency: Does client keep scheduled appointments: Yes No Inconsistent Current Overall Status/Barriers: 10
11 MENTAL HEALTH Psychiatric Care Identify Provider: * ed Identify psychotropic medication (These should be included on Medication page): Is client adhering to psychotropic medication regimen? Y N Inconsistent Individual/Family Counseling Support Group Bereavement Counseling Religious Support If yes to any of the above, indicate frequency: Does client/family keep scheduled appointments: Yes No Inconsistent Is client involved in any recreational/social activity: Yes No Inconsistent : Other: Current Overall Status/Barriers: 11
12 FAMILY STABILITY Children s Service s: Medical Educational Developmental Emotional Social Client/Collateral Service s: Guardianship/ Permanency Planning Child Abuse/Neglect Parenting Skills Child Care Respite Disclosure Domestic Violence Partner/Spousal ification * ed Is client linked with support systems? Yes No Inconsistent Identify: Other: Current Overall Status/Barriers: 12
13 LEGAL Legal Rights/Discrimination Will Living Will Health Care Proxy DNR Power of Attorney Criminal Justice Parole/Probation Immigration/Naturalization * ed Is client/family keeping legal appointments? Yes No Inconsistent Other: Current Overall Status/Barriers: 13
14 EMPLOYMENT/ EDUCATION GED/Education Job Readiness Assessment Job Training Job Placement Volunteer/Stipend * ed Has client returned to work or joined the workforce for the first time? Yes No If yes, PT/FT (> 20h/week): Other: Current Overall Status/Barriers: 14
15 PREVENTION EDUCATION REVIEW Date: * Discussion in all areas is required unless referral is made. Topic Referral ed Y/N HIV TB Hepatitis (A, B,C)/Vaccines STD Safer Sex Condoms Spermicide Dental Dam Drug Use le Sharing Use of Bleach Other Harm Reduction Techniques Universal Precautions Does client report consistent adherence to safer sex/harm reduction guidelines? Yes No Inconsistent Other: Current Overall Status/Barriers: 15
16 Ability to Perform Activities of Daily Living: If Assistance is Required, Recommended Care Environment: Who Currently Assists? Feeding Home Ambulating Alone Transferring Family Grooming Other Dressing Home with Support Bathing Homemaking Toileting Personal Care Homemaking Skilled Nursing Financial Management Hospital Preparing Meals Nursing Home Taking Medicine Supportive Housing Grocery Shopping Hospice Traveling ADHC Using Telephone Other Decision Making = By Self 1 = Some Assistance 2 = Total Assistance Other identified client/support system service needs or issues which need to be addressed: 16
17 Summary Comments/General Status of Client/Family: Indicate client s level of participation in goal achievement over the past quarter: Case Manager Signature Date Supervisor Signature Approval Date 17
Comprehensive Case Management Reassessment
Comprehensive Case Management Reassessment Reassessment Start Date: Reassessment Completion Date: Date of previous Assessment/Reassessment: Name: Client ID # Address: Phone: If Reassessment is early or
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ emtricitabine/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ emtricitabine/
GENERAL INSTRUCTIONS FOR COMPLETING THE HIV TEST FORM
GENERA INSTRUCTIONS FOR COMPETING THE This form is designed to be read by an Optical Character Recognition (OCR) scanner. The legibility of this form depends on the quality of the a hand written and selected
HIV 1. A reference guide for prescription HIV-1 medications
HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in
Presented by: Canadian Working Group on HIV and Rehabilitation
Rehabilitation in the Context of HIV: An Interprofessional Course for Occupational Therapists, Physiotherapists, Speech-Language Pathologists and Audiologists Presented by: Canadian Working Group on HIV
Treatment Information Service 1 800 HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition
HIV/AIDS Treatment Information Service 1 800 HIV 0440 HIV and Its Treatment What You Should Know 2nd edition HIV/AIDS TREATMENT INFORMATION SERVICE 2nd Edition HIV and Its Treatment: What You Should Know
Covered California s 2016 Formularies
Covered California s 2016 Formularies An analysis of the drugs per tier in all 12 health plans that are available for treating and preventing HIV (pp 1 24) and for treating hepatitis B (pp 26 37) and hepatitis
Drug Treatment Program Update
Drug Treatment Program Update As of May 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
HIV and the Central Nervous System: neurocognitive aspects VIH y Sistema Nervioso Central: aspectos neurocognitivos
HIV and the Central Nervous System: neurocognitive aspects VIH y Sistema Nervioso Central: aspectos neurocognitivos Gabriele Arendt Department of Neurology, University Hospital of Duesseldorf (UKD) 40
Helpful HIV Medication Tables for Pharmacists
861837_Pharmguide.qxd 2/5/14 12:55 PM Page 1 Helpful HIV Medication Tables for Pharmacists New York/New Jersey AIDS Education & Training Center (AETC) www.nynjaetc.org Winter 2014 861837_Pharmguide.qxd
862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1. Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians
862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1 Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians 2014 862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 2 Recreational Drugs
Systematic literature search: PICO questions
BHIVA Treatment Guidelines 2014: Systematic literature search questions Page 1 of 5 Systematic literature search: PICO questions 2.1 Questions and PICO criteria Databases: Medline, Embase, Cochrane Library,
CO-PAY PROGRAMS FOR HIV and Hepatitis
CO-PAY PROGRAMS FOR HIV and Hepatitis CO-PAY PROGRAMS FOR HIV These programs offer assistance to people with private health insurance for the co-payments they have to make at the pharmacy for their HIV
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS Stefano Vella Dipartimento del Farmaco Istituto Superiore di Sanità - Roma Stages of HIV-1 Life Cycle Targeted by Anti-HIV Drugs In: Gulick RM, Topics HIV
The Antiretroviral. Pregnancy Registry. Interim Report VOL. 28, NO. 1 1 JANUARY 1989 THROUGH 31 JANUARY 2016. Interim Report. (Issued: June 2016)
The Antiretroviral The Antiretroviral Pregnancy Registry Pregnancy Registry Interim Report VOL. 28, NO. 1 1 JANUARY 1989 THROUGH 31 JANUARY 2016 Interim Report (Issued: June 2016) VOL. (Expiration: 28,
Marketplace Health Plans Template Assessment Tool October 2014
Marketplace Health Plans Template Assessment Tool October 2014 Beginning in January 2015, state and federal Marketplaces (aka exchanges) will again offer a range of insurance plans called qualified health
Antiretroviral therapy for HIV infection in infants and children: Towards universal access
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
CDC occupation Codes used to code ( map ) facility locations
CDC occupation Codes used to code ( map ) facility locations CDC (occupation) Code BLS SOC (2000)* CDC (occupation) Code BLS SOC (2000)* ATT-Attendant/orderly 31-1012 CLA-Clerical/administrative CNA-Nurse
HIV Update: Epidemiology and Pathophysiology
HIV Update: Epidemiology and Pathophysiology MATEC Michigan AIDS Research and Education Center Wayne State University School of Medicine (313) 962-2000 matecmichigan.org 1 Epidemiology of the Epidemic:
1/26/2015. Epidemiology of the Epidemic: World. Epidemiology of the Epidemic: United States. HIV Update: Epidemiology and Pathophysiology
HIV Update: Epidemiology and Pathophysiology MATEC Michigan AIDS Research and Education Center Wayne State University School of Medicine (313) 962-2000 matecmichigan.org Epidemiology of the Epidemic: World
Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV
North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV Of North Carolina s marketplace insurance offerings, only Blue Cross Blue Shield s plans are potentially affordable
AIDS ACCESS FOUNDATION/ MSF AIDS can be Treated: A handbook of Antiretroviral medicines. AIDS Can Be Treated. A Hand Book of Antiretroviral medicines
AIDS Can Be Treated A Hand Book of Antiretroviral medicines The translation of this booklet is due to support from the Working Together Regional Training Project of the AIDS Access Foundation, Bangkok
Antiretroviral Patient Medication Information Sheets Table of Contents
Antiretroviral Patient Medication Information Sheets Table of Contents 1. About this Resource, Disclaimer, Instructions for Use 2. General information sheet - Provide this to all patients 3. Drug Specific
Generic antiretrovirals in Europe: a blessing or a curse?
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
ACA Insurance Enrollment for People living with HIV in North Carolina
ACA Insurance Enrollment for People living with HIV in North Carolina A Guide for the HIV Community In 2015, people living with HIV should take a fresh look at the insurance marketplace. Coverage will
A Guide to Primary Care of People with HIV/AIDS
2004 Edition A Guide to Primary Care of People with HIV/AIDS EDITORS John G. Bartlett, MD Professor of Medicine, Chief, Division of Infectious Diseases, and Director, AIDS Service The Johns Hopkins University
It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs. Jeff Berry Editor, Positively Aware
It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs Jeff Berry Editor, Positively Aware PAPs, Co-Pays, and ADAPs, Oh My! Patient Assistance Programs (PAPs) provide free or low-cost
A Guide to Primary Care of People with HIV/AIDS
2004 Edition A Guide to Primary Care of People with HIV/AIDS EDITORS John G. Bartlett, MD Professor of Medicine, Chief, Division of Infectious Diseases, and Director, AIDS Service The Johns Hopkins University
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
Chemotherapy regimen: Dose adjusted EPOCH
Chemotherapy regimen: Dose adjusted EPOCH Agents involved Etoposide 50 mg/m 2 /d continuous IV infusion D 1 4 Doxorubicin 10 mg/m 2 /d continuous IV infusion D 1 4 Vincristine 0.4 mg/m 2 /d IV continuous
HIV/AIDS 2014 REPORT MEDICINES IN DEVELOPMENT. Contents. Medicines and Vaccines in Development for HIV Infection
MEDICINES IN DEVELOPMENT HIV/AIDS PRESENTED BY AMERICA S BIOPHARMACEUTICAL RESEARCH COMPANIES 2014 REPORT Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV
Chapter 3 South African guidelines and introduction to clinical cases
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children
Ministry of Health National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children Edited by: Elly T. Katabira, FRCP Moses R. Kamya, M. Med, MPH, PhD Israel Kalyesubula, M. Med, DTCH
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example Prof. Dr. rer. nat. habil. Harald G. Schweim President Federal Institute
Patent Expiry Impact Predictor
Patent Expiry Impact Predictor Compiled and written by Datamonitor plc Datamonitor plc (DTML) is a premium business information company specialising in industry analysis and providing clients with unbiased
Social and Economic costs of HIV and AIDS. Current issues. Sarah Ann Adomakoh. Costs, cost-effectiveness & Sustainability
Associates for International Development Social and Economic costs of HIV and AIDS Current issues Suite A East Wing ARS Medicae Building No. 14, 6 th Avenue, Belleville St Michael Barbados Tel (246) 429
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
Antiretroviral Treatment
Antiretroviral Treatment Michael A. Tolle, MD, MPH Heidi Schwarzwald, MD, MPH Nancy R. Calles, MSN, PNP, ACRN, MPH Objectives 1. Discuss the goals of treatment for human immunodeficiency virus (HIV) infection.
Management of HIV and TB Co-infection in South Africa
Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy
Bristol-Myers Squibb and Gilead Sciences, LLC 50
Patient Information ATRIPLA (uh TRIP luh) Tablets ALERT: Find out about medicines that should NOT be taken with ATRIPLA. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA." Generic
AfricanEyeVOICE. Meet the world s strongest HIV Positive Campaigner: Milly Katana. plus Treatment News Treatment Q&A History of HIV and much more...
The AfricanEyeVOICE THE UK S FIRST AFRICAN HIV TREATMENT PUBLICATION February 10 - May 10 Meet the world s strongest HIV Positive Campaigner: Milly Katana plus Treatment News Treatment Q&A History of HIV
HIV. Head - Paediatric HIV Treatment Programmes. Right to Care. Dr Leon Levin
HIV Dr Leon Levin Head - Paediatric HIV Treatment Programmes Right to Care Disclaimer This talk represents my personal experience in managing teenagers with HIV over the last 14 years. It does not purport
People living. Since the start of the AIDS epidemic, more than 78 million people have been infected with HIV and 39 million have died (1).
THE GAP REPORT 2014 People living with HIV Since the start of the AIDS epidemic, more than 78 million people have been infected with HIV and 39 million have died (1). Acquiring HIV no longer means certain
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS. Weerawat Manosuthi
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS Weerawat Manosuthi Outline Case scenario of postexposure prophylaxis Risks of and how to manage postexposure prophylaxis Current PEP guideline US PHS 2013 New York
Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach
Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach Report of a WHO Working Group Meeting World Health Organization HIV Department Geneva, Switzerland 21-22
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013 VERSION 14 March 2013 Contents Acronym glossary... 2 1. Goals of the programme... 3 2. Objectives... 3 3. Specific Objectives... 3 4. Adults and
Ryan White Program Services Definitions
Ryan White Program Services Definitions CORE SERVICES Service categories: a. Outpatient/Ambulatory medical care (health services) is the provision of professional diagnostic and therapeutic services rendered
The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing firstline treatment regimen selection
DOI: 10.1111/j.1468-1293.2008.00561.x r 2008 Merck & Co., Inc. HIV Medicine (2008), 9, 285 293 ORIGINAL RESEARCH The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients
ACT. Advocacy for Community Treatment ITPC. Strengthening Community Responses to HIV Treatment and Prevention
ACT toolkit Advocacy for Community Treatment Strengthening Community Responses to HIV Treatment and Prevention ITPC INTERNATIONAL TREATMENT PREPAREDNESS COALITION July 2014 About ITPC ITPC is a worldwide
Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs
Access and coverage of antiretroviral drugs through Canada s provincial and territorial drug programs Provinces/Territory Drug Dose Form Alberta British Columbia Manitoba New Brunswick Newfoundland & Labrador
VILMA M. VEGA, M.D. CURRICULUM VITAE
VILMA M. VEGA, M.D. CURRICULUM VITAE MEDICAL LICENSE: Florida ME 0068013 MEDICAL EDUCATIONAL BACKGROUND 1993 1995 University of Miami, Jackson Memorial Hospital Miami, Florida. Fellowship in Infectious
Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV. National Guidelines
Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV National Guidelines National guidelines for post-exposure prophylaxis after non-occupational and occupational exposure
Republic of Namibia. Ministry of Health and Social Services Directorate of Special Programmes
Republic of Namibia Ministry of Health and Social Services Directorate of Special Programmes National Guidelines for Antiretroviral Therapy Fourth Edition January 2014 Enquiries: [email protected] 1 Foreword
National Antiretroviral Treatment Guidelines
National Antiretroviral Treatment Guidelines Copyright 2004 Department of Health Published by Jacana Printed by Minuteman Press ISBN: 1-919931-69-4 National Department of Health South Africa 2004 This
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
ARV treatment Update 2012. Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen
ARV treatment Update 2012 Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen Three big conferences in 2012 http://retroconference.org/2012/ http://www.aids2012.org/ http://www.hiv11.com/ Current
Ryan White Part A Quality Management
Ryan White Part A Quality Management Medical Case Management Service Delivery Model Palm Beach County Table of Contents Statement of Intent 3 Service Definition..3 Practitioner Definition...3 Practitioner
From Drug Holidays to 100% Adherence- The Role of the Pharmacist in HIV Drug Therapy - FL APPROVED -
From Drug Holidays to 100% Adherence- The Role of the Pharmacist in HIV Drug Therapy - FL APPROVED - ACTIVITY DESCRIPTION In the mid 1990 when multiple drug regimens HIV cocktails became available, drug
